Kenvue, Inc. (KVUE)

Over the past six months, Kenvue's stock price has experienced fluctuations and underperformed the S&P 500 Index by -7.2%. In Q1 2025, Kenvue reported earnings per share of $0.24 and revenue of $3.74 billion, exceeding estimates, which led to a share price increase. The CEO's comments on seasonal demand challenges caused a stock price decrease. Kenvue adjusted its FY25 EPS guidance due to tariffs but revised net sales growth guidance upward. The company disclosed a quarterly dividend of $0.205 per share.

Demand for Kenvue's products is subject to seasonality, especially for allergy and sun protection products. A prolonged winter can delay the allergy and sun season, impacting sales, while a strong cold and flu season can positively impact brands like Tylenol. Kenvue acknowledges that it is not immune to seasonal variability in parts of its portfolio.

Kenvue Inc. is an American consumer health company spun off from Johnson & Johnson in 2023 and publicly traded on May 4, 2023. It operates in the Personal Care Products industry, aiming to promote health and well-being through innovative products. The company is divided into three segments: Self Care, Skin Health and Beauty, and Essential Health, encompassing a range of well-known brands.

Kenvue has a significant global presence, selling and distributing its products in over 165 countries across four regions: North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). Approximately half of its net sales were generated outside North America in 2021. The company has a global team of over 20,000 employees and 25 in-house manufacturing facilities. Kenvue's global headquarters are located in Summit, New Jersey.

Kenvue has a strong brand reputation due to its portfolio of trusted consumer health brands, demonstrated by its debut on the Fortune 500 list. However, the company faces ongoing litigation risk inherited from Johnson & Johnson, which could divert financial resources and harm its brand reputation.

Kenvue Inc. is primarily owned by institutional shareholders, who hold approximately 97.96% of the company's stock. Major institutional owners include Vanguard Group Inc., Price T Rowe Associates Inc /md/, BlackRock, Inc., and State Street Corp. Johnson & Johnson is the largest individual shareholder, owning 9.50% of the company.